- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770653
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Insulin resistance is a major endocrinopathy preceding the development of hyperglycemia, diabetic dyslipidemia and cardiovascular disease in type 2 diabetes. The most common pattern of dyslipidemia in patients with type 2 diabetes are elevated triglyceride levels, decreased hih-density lipoprotein cholesterol and a predominance of small dense low-density lipoprotein particles. Each of these dyslipidemia features is associated with an increased risk of cardiovascular events.
Pioglitazone and Metformin are established drugs which can be used for the treatment of type 2 diabetes. This study will investigate the effects of treatment with fixed Pioglitazone/Metformin combination therapy of Metformin and Glimepiride in Metformin-pretreated type 2 diabetic patients with dyslipidemia.
Total participation time in this study is anticipated to be approximately 24 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
-
Hamburg, Germany
-
-
Baden-Württemberg
-
Bretten, Baden-Württemberg, Germany
-
Deggingen, Baden-Württemberg, Germany
-
Dettenheim, Baden-Württemberg, Germany
-
Künzelsau, Baden-Württemberg, Germany
-
Rottweil, Baden-Württemberg, Germany
-
Spaichingen, Baden-Württemberg, Germany
-
Stockach, Baden-Württemberg, Germany
-
Wangen, Baden-Württemberg, Germany
-
-
Bayern
-
Augsburg, Bayern, Germany
-
Feldafing, Bayern, Germany
-
Furth im Wald, Bayern, Germany
-
Immenstadt, Bayern, Germany
-
Lichtenfels, Bayern, Germany
-
München, Bayern, Germany
-
Schweinfurt, Bayern, Germany
-
Waldkraiburg, Bayern, Germany
-
Wallerfing, Bayern, Germany
-
Weilersbach, Bayern, Germany
-
Würzburg, Bayern, Germany
-
-
Brandenburg
-
Ketzin, Brandenburg, Germany
-
Rüdersdorf, Brandenburg, Germany
-
-
Bremen
-
Bermerhaven, Bremen, Germany
-
-
Hessen
-
Bensheim, Hessen, Germany
-
Ehrenberg, Hessen, Germany
-
Gersfeld, Hessen, Germany
-
Kassel, Hessen, Germany
-
Kelkheim, Hessen, Germany
-
Offenbach, Hessen, Germany
-
-
Mecklenburg-Vorpommern
-
Schwerin, Mecklenburg-Vorpommern, Germany
-
-
Niedersachsen
-
Celle, Niedersachsen, Germany
-
Einbeck, Niedersachsen, Germany
-
Hannover, Niedersachsen, Germany
-
Hildesheim, Niedersachsen, Germany
-
-
Nordrhein-Westfalen
-
Bad Berleburg, Nordrhein-Westfalen, Germany
-
Bad Laasphe, Nordrhein-Westfalen, Germany
-
Bad Oeynhausen, Nordrhein-Westfalen, Germany
-
Bocholt, Nordrhein-Westfalen, Germany
-
Dinslaken, Nordrhein-Westfalen, Germany
-
Dorsten, Nordrhein-Westfalen, Germany
-
Duisburg, Nordrhein-Westfalen, Germany
-
Essen, Nordrhein-Westfalen, Germany
-
Frechen, Nordrhein-Westfalen, Germany
-
Isselburg, Nordrhein-Westfalen, Germany
-
Kamen, Nordrhein-Westfalen, Germany
-
Köln, Nordrhein-Westfalen, Germany
-
Marl, Nordrhein-Westfalen, Germany
-
Menden, Nordrhein-Westfalen, Germany
-
Münster, Nordrhein-Westfalen, Germany
-
Siegen, Nordrhein-Westfalen, Germany
-
-
Rheinland-Pfalz
-
Diez, Rheinland-Pfalz, Germany
-
Mainz, Rheinland-Pfalz, Germany
-
Neuwied, Rheinland-Pfalz, Germany
-
Rodenbach, Rheinland-Pfalz, Germany
-
Simmern, Rheinland-Pfalz, Germany
-
-
Sachsen
-
Borna, Sachsen, Germany
-
Dresden, Sachsen, Germany
-
Meißen, Sachsen, Germany
-
Mittweida, Sachsen, Germany
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Germany
-
-
Schleswig-Holstein
-
Reinfeld, Schleswig-Holstein, Germany
-
-
Thüringen
-
Altenburg, Thüringen, Germany
-
Blankenhain, Thüringen, Germany
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes according to the American Diabetes Association Criteria.
- Treatment with individual maximal tolerated dose of metformin (850 - 2000 mg) as monotherapy within the last 12 weeks.
- Glycosylated Hemoglobin greater than or equal to 6.5% and less than or equal to 9%.
- Dyslipidemia defined as high-density lipoprotein cholesterol less than or equal to 1.03 mmol/l (40 mg/dL) and/or triglycerides greater than or equal to 1.7 mmol/l (150 mg/dL).
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria:
- Type 1 diabetes mellitus.
- Insulin-dependent type 2 diabetes mellitus.
- Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks.
- Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks.
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Heparin (and heparin-like drugs)
- coumarin
- phenprocoumon
- hirudin
- Protein C
- Fondaparinux
- antithrombin III
- Peroxisome Proliferation Activating Receptor (gamma) agonists
Treatment within the last 12 weeks with:
- fibrates
- gemfibrozil
- niacin
- months
- Rifampicin
- Changes in dosage of any statin treatment to lower low-density lipoprotein within 2 weeks before study entry and during study participation interval.
- Changes in dosage of any anticoagulant treatment with acetyl salicylic acid and/or clopidogrel within 2 weeks before study entry and during study participation interval.
- Start of statin and/or anticoagulant treatment during study participation interval.
- History of severe or multiple allergies and/ or acute severe infections.
- Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.
- Progressive fatal disease.
- Any elective surgery during study participation.
- History of drug or alcohol abuse within the last 5 years.
- A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase and/or aspartate aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, glomerular filtration rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema.
- Blood donation within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pioglitazone 15 mg and Metformin 850 mg BID
|
Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
Other Names:
|
ACTIVE_COMPARATOR: Glimepiride 2 mg and Metformin 850 mg BID
|
Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.
Time Frame: Baseline and Week 24.
|
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
|
Baseline and Week 24.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in High-Density Lipoprotein Cholesterol.
Time Frame: Baseline and Week 24.
|
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.
Time Frame: Baseline and Week 24.
|
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Triglycerides.
Time Frame: Baseline and Week 24.
|
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Low-Density Lipoprotein Subfractions.
Time Frame: Baseline and Week 24.
|
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Low-Density Lipoprotein Cholesterol.
Time Frame: Baseline and Week 24.
|
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Glycosylated Hemoglobin.
Time Frame: Baseline and Week 24.
|
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Fasting Intact Proinsulin.
Time Frame: Baseline and Week 24.
|
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Fasting Glucose.
Time Frame: Baseline and Week 24.
|
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Adiponectin.
Time Frame: Baseline and Week 24.
|
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in High Sensitivity C-reactive Protein (Original).
Time Frame: Baseline and Week 24.
|
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).
Time Frame: Baseline and Week 24.
|
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Systolic Blood Pressure.
Time Frame: Baseline and Week 24.
|
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Diastolic Blood Pressure.
Time Frame: Baseline and Week 24.
|
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.
|
Baseline and Week 24.
|
Intake of Study Medication Greater Than 80% and Less Than 120%.
Time Frame: Baseline and Week 24.
|
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Nitrotyrosine.
Time Frame: Baseline and Week 24.
|
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Soluble CD40 Ligand.
Time Frame: Baseline and Week 24.
|
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Matrix Metallo Proteinase-9.
Time Frame: Baseline and Week 24.
|
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Soluble Intracellular Adhesion Molecule.
Time Frame: Baseline and Week 24.
|
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Soluble Vascular Cell Adhesion Molecule.
Time Frame: Baseline and Week 24.
|
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Thromboxane B2.
Time Frame: Baseline and Week 24.
|
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Platelet Function.
Time Frame: Baseline and Week 24.
|
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in E-Selectin.
Time Frame: Baseline and Week 24.
|
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Von-Willebrand Factor.
Time Frame: Baseline and Week 24.
|
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (0.30%).
Time Frame: Baseline and Week 24.
|
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (0.60%)
Time Frame: Baseline and Week 24.
|
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (1.20).
Time Frame: Baseline and Week 24.
|
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (3.00).
Time Frame: Baseline and Week 24.
|
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (6.00).
Time Frame: Baseline and Week 24.
|
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (12.00).
Time Frame: Baseline and Week 24.
|
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (30.00).
Time Frame: Baseline and Week 24.
|
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Change From Baseline in Erythrocyte Deformability (60.00).
Time Frame: Baseline and Week 24.
|
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.
|
Baseline and Week 24.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATS K024
- 2006-004455-37 (EUDRACT_NUMBER)
- D-PIO-114 (OTHER: Takeda Pharma GmbH)
- U1111-1114-1678 (REGISTRY: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pioglitazone and Metformin
-
Huazhong University of Science and TechnologyHubei Xinhua Hospital; Wuhan Iron and Steel Workers' Hospital; Wuhan Pu-Ai HospitalCompletedDiabetes Mellitus, Type 2China
-
University of MinnesotaNot yet recruitingOral LeukoplakiaUnited States
-
King Edward Medical UniversityCompleted
-
Postgraduate Institute of Medical Education and...Council of Scientific and Industrial Research, IndiaWithdrawn
-
Khyber Medical University PeshawarCompletedPolycystic Ovarian SyndromePakistan
-
Daiichi Sankyo, Inc.CompletedDiabetes Mellitus, Type 2United States
-
Xiang Guang-daCompletedEndothelial Function | LVM | Type 2 Diabetic Patients With IHDChina
-
Bing HeActive, not recruitingPolycystic Ovary SyndromeChina
-
Dow University of Health SciencesUnknownHyperandrogenism | Menstrual IrregularitiesPakistan
-
TakedaCompleted